AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 11 min read

Medpace President & CEO Sold Shares Worth Over $30M

Medpace's President & CEO August J. Troendle sold 49,100 shares in two transactions on 2026-09-29 and 2026-09-30, totaling $30.3M. He now directly owns 338,225 shares and indirectly owns 4.7M shares via Medpace Investors, LLC, according to SEC filings.

Original reporting
tradingview.com
Published Oct 1, 2026, 9:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 9:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Medpace President & CEO Sold Shares Worth Over $30M — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

The disclosed sale is the first public report of this transaction, making it a primary news event.

02

Market read

A $30M insider sell by the CEO is a material event that can influence Medpace's share price and investor sentiment.

03

What to watch

Potential tax planning or liquidity needs for the CEO; no immediate operational issues disclosed.

Relevance 6/10Novelty 7/10Timing: post‑market today

Background

Form 4 filing reveals insider transactions; such disclosures are primary sources for insider activity.

Market effects

Sector

May prompt scrutiny of other biotech insider transactions and affect sector sentiment.

Regional

Limited to U.S. markets where Medpace trades.

Global

Low; impact confined to the company and its niche sector.

Counterpoint

What could challenge this read

The sale could be a portfolio rebalancing unrelated to company fundamentals; the stock may remain stable.

Key entities

  • Person
    August J. Troendle

    President & CEO of Medpace, 10% shareholder

  • Company
    Medpace

    Clinical research organization listed on Nasdaq

Read at source← All news

Related articles

OCT 23
$MEDPMedAI 8/10

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

finance.yahoo.com2 min
OCT 22
$MEDPMedAI 8/10

Medpace 3Q 2026: Revenue $716M, EPS $4.84— 10-Q Summary

Medpace Holdings reported Q3 2026 revenue of $716M, up 8.5% YoY, with net income rising 23.7% to $137.46M and EPS increasing 25.4% to $4.84. Growth was driven by Metabolic, Oncology, and CNS services. Nine-month revenue grew 16.9%, net awards reached $873.4M, and backlog increased 5.6% YoY to $3.17B. The company plans organic growth and selective acquisitions.

tradingview.com2 min
OCT 22
$MEDPHighAI 8/10

Medpace (MEDP) Q3 2026 Earnings Call Transcript

Medpace (MEDP) reported Q3 2026 revenue of $716M, up 8.5% YoY, with EBITDA of $172.1M (up 16%) and net income of $137.5M (up 23.7%). Guidance raised: revenue $2.835B-$2.855B (12-12.8% growth), EBITDA $638M-$652M (14.4-16.9% growth), EPS $17.97-$18.32. Board approved $1B share repurchase program. Net new business awards up 10.6% QoQ.

finance.yahoo.com2 min
OCT 22
$MEDPMed

Medpace Q3 Earnings Call Highlights

Medpace reported a 10.6% year-over-year increase in net new business awards to $873.4 million in Q3, with a total 12-month backlog of $3.02 billion. Ending backlog was $3.2 billion, up 5.6% year-over-year. The company expects $1.99 billion of backlog to convert into revenue over the next year. Management noted shifts in therapeutic mix and strong pending opportunities. Medpace plans to provide 2027 guidance in February, with fourth-quarter awards and cancellations influencing the outlook.

finance.yahoo.com2 min
OCT 22
$MEDPHighAI 8/10

Medpace Q3 2026 slides: record awards fuel profit beat, guidance raised

Medpace Holdings (NASDAQ:MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and adjusted earnings of $4.84 per share, exceeding estimates. Net income rose 23.7% to $137.5M, with EBITDA margin widening to 24.0%. The company raised its full-year guidance, citing record new business awards and strong profitability trends. Shares traded near $659.37, close to their 52-week high.

investing.com2 min